Finance

Beta
Lists
TNGX:NASDAQ
Tango Therapeutics Inc
$30.12
+0.60%
(+0.18) 1D
$30.12
0.00% (0.00)
After hours
Closed: Jul 7, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNGX...
Open
$30.35
High
$30.81
Low
$29.19
Mkt. cap
4.89B
Avg. vol.
5.34M
Volume
2.80M
52-wk high
$34.39
52-wk low
$5.48
EPS
-$0.83
Beta
1.12
Shares outstanding
162.82M
No. of employees
137
Open
$30.35
High
$30.81
Low
$29.19
Mkt. cap
4.89B
Avg. vol.
5.34M
Volume
2.80M
52-wk high
$34.39
52-wk low
$5.48
EPS
-$0.83
Beta
1.12
Shares outstanding
162.82M
No. of employees
137
News stories
From sources across the web
About Tango Therapeutics Inc
CEO-
Employees137
Founded2017
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websitetangotx.com
Analyst ratings
Based on 11 analysts giving stock ratings to TNGX in the past 3 months
Strong buy
Buy
10
Hold
1
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for TNGX in the last 3 months.
Highest
Current $30.12
$66.00 (+119.12%)
Average
$42.00 (+39.44%)
Lowest
$24.00 (-20.32%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Newman
Canaccord Genuity
Buy
Maintained
$46.00
+52.7%
06/29/2026
Maury Raycroft
Jefferies
Buy
Upgraded
$60.00
+99.2%
06/26/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$32.00
+6.2%
06/09/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$66.00
+119.1%
06/10/2026
Joseph Catanzaro
Mizuho Securities
Buy
Reiterated
$36.00
+19.5%
06/08/2026
Kalpit Patel
Wolfe Research
Buy
Upgraded
$35.00
+16.2%
06/08/2026
Yuan Zhi
B. Riley Securities
Buy
Reiterated
$35.00
+16.2%
06/09/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$32.00
+6.2%
06/01/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
$40.00
+32.8%
05/25/2026
Kelsey Goodwin
Piper Sandler
Hold
Downgraded
$24.00
-20.3%
05/15/2026
Andrew Berens
Leerink Partners
Buy
Reiterated
$55.00
+82.6%
05/15/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$33.00
+9.6%
05/14/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
3.18M
53.81M
-
-
Cost of goods sold
32.81M
30.82M
32.10M
33.53M
Cost of revenue
32.81M
30.82M
32.10M
33.53M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.34M
8.92M
9.76M
15.24M
Operating expense
11.34M
8.92M
9.76M
15.24M
Total operating expenses
44.15M
39.74M
41.86M
48.77M
Operating income
-40.97M
14.07M
-41.86M
-48.77M
Other non operating income
910.00K
705.00K
3.30M
-45.00K
EBT including unusual items
-38.82M
15.87M
-38.80M
-45.51M
EBT excluding unusual items
-38.82M
15.87M
-36.88M
-46.64M
Income tax expense
35.00K
-10.00K
-55.00K
1.00K
Effective tax rate
-0.09%
-0.06%
0.14%
-
Other operating expenses
-
-
-
-
Net income
-38.85M
15.88M
-38.75M
-45.51M
Net profit margin
-1,221.41%
29.52%
-
-
Earnings per share
-0.35
0.13
-0.29
-0.32
Interest and investment income
1.24M
1.10M
1.68M
2.18M
Interest expense
-
-
-
-
Net interest expenses
1.24M
1.10M
1.68M
2.18M
Depreciation and amortization charges
-
-
-
-
EBITDA
-40.34M
14.63M
-41.38M
-48.31M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer